News

Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2021 and raised 2021 guidance⁽³⁾ for revenues and Adjusted diluted EPS⁽²⁾ driven by the updated expectations for contributions

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in fireside chats at the following investor conferences:

• 
  BofA
  

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die starken Ergebnisse der operativen Tätigkeit für das erste Quartal 2021 bekannt. Das Unternehmen hat seine Ziele für den

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced strong results of operations for the first quarter of 2021, exceeding the goals for net sales and adjusted earnings per share.

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210502005042/en/

Regulatory News:

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within

Regulatory News:

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced positive results from a phase-III study in China (PA-CL-CHINA-01), evaluating the efficacy of Velphoro^® (PA21)

Regulatory News:

NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Einführung der EZ2-Connect-Produktlinie angekündigt. Mit seiner neuen Plattform hebt das Unternehmen die Probenverarbeitung auf

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the upcoming launch of the EZ2 Connect product line, a next-level automated sample-processing platform whose simplicity

IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines to fight against infectious

Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2021, highlighting continued commercial strength despite changes in patterns of care in some regions driven

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005922/en/

Vifor Pharma and Angion Biomedica Corp. (NASDAQ

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Bank of America 2021 Health Care Conference on Tuesday

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today

ICON plc (NASDAQ: ICLR), a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health

Regulatory News:

NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today

€1.5 million guaranteed by the French government (PGE) and granted by BNP bank  €1.5 million innovation and R&D loan granted by Bpifrance Funding will allow for acceleration of R&D programs

Quantum

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Charles Triano, Senior Vice President, Investor Relations, at the 7th Annual Truist

Pfizer Inc. (NYSE: PFE) announced today that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its first quarter 2021 financial results on Thursday, May 6, 2021, after the markets

Regulatory News:

Vifor Pharma today announced that the first patient has been enrolled in the large scale registry CARE-HK in HF (cardiovascular and renal treatment in HF patients with or at high

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced upcoming data presentations at the 24^th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)